Preparation and in vitro characterization of alginate microspheres encapsulated with autoclaved leishmania major (ALM) and CpG-ODN

Iranian Journal of Basic Medical Sciences

Volumn 10, Issue 2, 2007, Pages 90-98

  Ghiasi, Z ^a   Tabasi, S A Sajadi ^b   Tafaghodi, M ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant; Alginate microsphere; CpG ODN; Immunization; Leishmaniasis

Indexed keywords

ALGINIC ACID; CPG OLIGODEOXYNUCLEOTIDE; MICROSPHERE;

ARTICLE; BIODEGRADATION; DRUG ANTIGENICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EMULSION; ENCAPSULATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; LEISHMANIA MAJOR; LEISHMANIASIS; MICROBIAL ATTENUATION; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POROSITY; PROTEIN DETERMINATION; SCANNING ELECTRON MICROSCOPY; SLOW DRUG RELEASE; SPECTROPHOTOMETRY; STAINING; ULTRASOUND; VISCOSITY;

EID: 64249095703     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: 10.22038/IJBMS.2007.5275     Document Type: Article

References (25)

1. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001; 14: 229-243.
2. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 1995; 89: 83-88.
3. Satti I N, Osman H Y, Daifalla N S, Younis S A, Khalil E A, Zijlstra E E, e t al. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 2001; 19:2100-2106.
4. Follador I, Araujo C, Orge G, Cheng L H, de Carvalho L P, Bacellar O, et al. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colonystimulating factor. Vaccine 2002; 20: 1365-1368.
5. Fundueanu G, Esposito E, Mihai D, Carpov A, Desbrieres J, Rinaudo M, et al. Preparation and characterization of Ca-alginate microspheres by a new emulsification method. Int J Pharm 1998; 170: 11-21.
6. Lemoine D, Wauters F, Bouchend’homme S, Preat V.Preparation and characterization of alginate microspheres containing a model antigen. Int J Pharm 1998; 176: 9-19.
7. Tafaghodi M, Jaafari M R, Sajadi Tabasi S A. Nasal immunization studies by liposomes encapsulated with tetanus toxoid and CpG-ODN. Eur J Pharm Biopharm 2006; 64: 138-145.
8. Mittal S K, Aggarwal N, Sailaja G, van Olphen A, HogenEsch H, North A, et al. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2000; 19: 253-263.
9. Gupta R K, Siber G R. Adjuvants for human vaccines--current status, problems and future prospects. Vaccine 1995; 13: 1263-1276.
10. Krieg A M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.Biochim. Biophys Acta (BBA) - Gene Structure and Express 1999; 1489: 107-116.
11. Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, Klinman D, et al. Coinjection with CpGcontaining immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect Immun 2003; 71: 5121-5129.
12. Rhee E G, Mendez S, Shah J A, Wu C Y, Kirman J R, Turon T N, et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J Exp Med 2002; 195: 1565-1573.
13. Verthelyi D, Kenney R T, Seder R A, Gam A A, Friedag B, Klinman D M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 2002; 168: 1659-1663.
14. Diwan M, Tafaghodi MSamuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Rel 2002; 85: 247-262.
15. Tafaghodi M. Nasal immunization using biodegradable microspheres and liposomes: tetanus toxoid as a model. Ph.D. Thesis, Mashhad: University of Medical Sciences; 2003.
16. Tafaghodi M, Sajadi Tabasi S A, Jaafari M R. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm 2006; 319: 37-43.
17. Tafaghodi M, Sajadi Tabasi S A, Jaafari M R. Formulation and characterization and release studies of alginate microsphere encapsulated with tetanus toxoid. J Biomat Sci Polymer Ed 2006; 17: 909-924.
18. Waterborg J H. Quantitation of proteins. In: Walker J. (ed.). The Protein Protocols Handbook. Newjersey:Humana Press; 2002. 3-36.
19. Barman S P, Lunsford L, Chambers P, Hedley M L. Two methods for quantifying DNA extracted from poly (lactide-co-glycolide) microspheres. J Control Rel 2000; 69: 337-344.
20. Sinha V R, Trehan A. Biodegradable microspheres for protein delivery. J Control Rel 2003; 90: 261-280.
21. Vandenberg G W, Drolet C, Scott S L, De la Noue J. Factors affecting protein release from alginatechitosan coacervate microcapsules during production and gastric/intestinal simulation. J Control Rel 2001; 77: 297-307.
22. Al-Musa S, Abu Fara D, Badwan A A. Evaluation of parameters involved in preparation and release of drug loaded in crosslinked matrices of alginate. J Control Rel 1999; 57: 223-232.
23. Freiberg S, Zhu X X. Polymer microspheres for controlled drug release. Int J Pharm 2004; 282: 1-18.
24. Freitas S, Merkle H P, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Rel 2005; 102: 313-332.
25. Kahl L P, Lelchuk R, Scott C A, Beesley J. Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis. Infect Immun 1990; 58: 3233-3241.